Cytek Biosciences (CTKB) AI Stock Analysis

• Market Cap: $474.97M
• Dividend Yield: N/A
• Average Volume (3M): 1.08M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -1.86%
• EPS Growth: -2.01%
• Country: US
• Employees: 663
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.09
• Shares Outstanding: 126,659,195
• 10 Day Avg. Volume: 877,244
• 30 Day Avg. Volume: 1,083,229
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.75
• Price Target Upside: 53.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 65 Neutral
• Price Target: $4.00 ▲(6.67%Upside)

The stock's overall score is driven by strong gross profitability and a solid balance sheet. However, challenges in achieving net profitability, negative valuation metrics, and mixed guidance from the earnings call impact the overall score. Technical indicators offer some positive momentum, but the valuation concerns and market uncertainties weigh heavily.

Positive Factors

Global Market Growth

Management reported strong growth in Asia Pacific and Rest Of World markets, offering some positive outlook despite current challenges.

Service Revenue Performance

Service revenue grew significantly driven by growth in the instrument installed base.

Negative Factors

Competition Impact

CTKB's sales have been impacted by Becton Dickinson's new S8 Cell Sorter launch, leading to a preliminary revenue miss.

Geopolitical and Funding Concerns

Challenges are anticipated in CTKB's global academic and government end market due to geopolitical concerns and NIH funding visibility.

Revenue Miss

The company missed its top and bottom line targets due to multiple persistent challenges.

Cytek Biosciences Business Overview & Revenue Model

Company Description

Cytek Biosciences (CTKB) is a biotechnology company that specializes in the development and manufacturing of flow cytometry products. The company operates in the life sciences and healthcare sectors, providing advanced cell analysis systems and related reagents and software. Cytek's core products are designed to offer comprehensive and high-dimensional cell analysis solutions, which are utilized in various applications including immunology, cancer research, and drug discovery.

How the Company Makes Money

Cytek Biosciences generates revenue primarily through the sale of its flow cytometry systems, which include hardware, software, and associated reagents. The company offers a range of products tailored to different research and clinical needs, allowing it to cater to a wide customer base, including academic institutions, pharmaceutical companies, and clinical research organizations. In addition to product sales, Cytek may also derive income from service contracts, maintenance agreements, and training programs. Strategic partnerships and collaborations with other companies and research institutions can further contribute to its earnings by expanding its market reach and driving product innovation.

Cytek Biosciences Financial Statement Overview

Summary

Cytek Biosciences shows strong gross profitability and a solid balance sheet with low leverage. However, the company struggles with net profitability and consistent positive cash flow, which are crucial for improving financial health.

Income Statement

The company has shown a fluctuating revenue trend with a recent decline in TTM revenue. Gross profit margins remained strong at approximately 55%. However, net profit margins are negative due to persistent net losses. Despite a negative EBIT margin, the company maintains a relatively stable EBITDA margin due to lower depreciation and amortization costs. Overall, the income statement reflects a mix of stable gross profitability but challenges in achieving net profitability.

Balance Sheet

The balance sheet is marked by a strong equity position with a high equity ratio of 78.7%, indicating financial stability. The debt-to-equity ratio is very low, signifying minimal leverage usage. Despite the strong equity position, return on equity is negative due to net losses. The company maintains a robust cash position, which supports its financial resilience.

Cash Flow

The cash flow statement indicates a positive free cash flow in the TTM period, recovering from negative cash flows in prior years. Operating cash flow to net income ratio is positive, highlighting efficient cash generation relative to net losses. However, free cash flow to net income ratio remains challenged due to substantial capital expenditures in previous years. Overall, cash flows show improvement, but consistent generation of positive free cash flow is required for stronger performance.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cytek Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTKB, the sentiment is Positive. The current price of 3.75 is above the 20-day moving average (MA) of 3.42, above the 50-day MA of 3.18, and below the 200-day MA of 4.69, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 62.30 is Neutral, neither overbought nor oversold. The STOCH value of 87.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTKB.

Cytek Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTKB	65 Neutral	$474.97M	―	-2.91%	―	-1.86%	-2.01%
MASS	59 Neutral	$262.86M	―	-44.97%	―	21.06%	-99.70%
Sector *	57 Neutral	£4.92B	6.91	-62.36%	2.24%	34.00%	6.32%
PACB	53 Neutral	$492.14M	―	-177.29%	―	-23.99%	-100.40%
BFLY	50 Neutral	$479.74M	―	-29.16%	―	25.77%	49.44%
SGHT	47 Neutral	$183.03M	―	-52.87%	―	-4.16%	12.79%
TLSI	47 Neutral	$172.79M	―	271.41%	―	85.03%	53.73%

Cytek Biosciences Corporate Events

Cytek Biosciences Elects New Directors at Annual Meeting

On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.

The most recent analyst rating on (CTKB) stock is a Buy with a $8.25 price target. To see the full list of analyst forecasts on Cytek Biosciences stock, see the CTKB Stock Forecast page.